North Dakota
Prescription drug spending and prescribing in North Dakota, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $549M for prescriptions written in North Dakota, the 49th most of 52 states and territories, and 3.0% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $549M
- Medicaid drugs, 2025: $105M
- Opioid share of claims: 3.0%
- Life-science raises, 2 years: $9M
Opioid Share of Part D Claims, 2024
North Dakota outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
North Dakota Against the Nation
Share of Part D claims; dark is the state, light the US.
- Opioids, North Dakota3%
- Opioids, US3.5%
- Antibiotics, North Dakota3.9%
- Antibiotics, US4.4%
- Antipsychotics, North Dakota1.8%
- Antipsychotics, US1.7%
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | North Dakota | United States | Difference |
|---|---|---|---|
| Opioids | 3.0% | 3.5% | -16% |
| Antibiotics | 3.9% | 4.4% | -12% |
| Antipsychotics | 1.8% | 1.7% | +5% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of North Dakota's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Pen Needle,dual Safety,diabetc | 4.2× | 4,124 |
| Insulin Aspart (Niacinamide) | 2.9× | 3,600 |
| Warfarin Sodium | 2.5× | 32,339 |
| Bumetanide | 2.4× | 14,625 |
| Calcitriol | 2.3× | 7,869 |
| Liraglutide | 2.3× | 2,059 |
| Peg3350/Sod Sulf,bicarb,cl/Kcl | 2.3× | 8,499 |
| Mometasone/Formoterol | 2.2× | 2,078 |
| Metolazone | 2.2× | 3,627 |
| Roflumilast | 2.2× | 2,160 |
Biggest Medicaid Drugs
What North Dakota's Medicaid program paid pharmacies, before rebates; see every drug| Drug | Paid, 2025 |
|---|---|
| Humira | $10M |
| Sofosbuvir | $5M |
| Vraylar | $4M |
| Jardiance | $4M |
| Vyvanse | $4M |
| Taltz | $4M |
| Dupixent | $4M |
| Invega | $3M |
| Norditropi | $3M |
| Keytruda | $2M |
Life-Science Fundraising
4 Form D raises by companies based in North Dakota in the last two years; the 10 largest. See all raises- CorVent Medical, Inc.$5M · Other health care · Dec 13, 2024
- CorVent Medical, Inc.$4M · Other health care · Dec 30, 2024
- Bench7 Inc.$100K · Biotech · Mar 20, 2025
- Edgewood OpCo, LLC$25K · Other health care · Dec 16, 2024
State Attorney General Health-Care Cases
Antitrust cases North Dakota joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG